• UNIVERSITY STUDIES – 1990-1996, “Gr.T. Popa” University of Medicine and Pharmacy, General Medicine Specialization, Generalist title
• POSTGRADUATE STUDIES – 1997-2002, “Gr.T. Popa” University of Medicine and Pharmacy, Infectious Diseases Specialization, title obtained Infectious Diseases Specialist
• Doctorate – University of Medicine and Pharmacy “Gr.T. Popa”, field of Medicine – Infectious Diseases, title of the doctoral thesis “Tuberculous meningitis in children – clinical considerations, therapeutic and evolutionary diagnoses”, year of defense 2014, doctorate.

• 2003-2004, “Gr.T.Popa” University of Medicine and Pharmacy, Iaşi, Homeopathy course
• 2018-2019, “Gr.T.Popa” University of Medicine and Pharmacy Iaşi, General Ultrasonography Course
• October 25-29, 2003, EACS, 1st EACS Resistance & Pharmacology Worshop, October 2003, Warsaw, Poland
• February 14-16, 2008, Institute of Gastroenterology and Hepatology Iasi, Intensive Gastroenterology Course
• February 25, 2016, “Gr.T. Popa” University of Medicine and Pharmacy Iaşi, Keyrus Biopharma, Scientific Abstract and Poster Workshop
• December 6-8, 2013, “Gr.T. Popa” University of Medicine and Pharmacy, Iaşi, Postgraduate course “Medical and traumatic emergencies”
• December 3-5, 2013, “Gr.T. Popa” University of Medicine and Pharmacy, Iaşi Postgraduate course “Basic and advanced cardiopulmonary resuscitation”
• June 19-21, 2014, “Gr.T. Popa” University of Medicine and Pharmacy, Iaşi, Summer Medical School with the topic “Infectious pathology – transdisciplinary vision in the era of globalization”

• 2008- at present, Primary Care Medic – County Emergency Hospital „St. Ioan cel Nou ” Suceava, field of activity Infectious Diseases,
• 2020-present, Lecturer “Stefan cel Mare” University of Suceava, Faculty of Medicine and Biological Sciences.
• 2002- 2008, Specialist doctor – County Emergency Hospital „St. Ioan cel Nou ” Suceava, field of activity Infectious Diseases,
• 1997 – 2002, Resident doctor – Iasi Infectious Diseases Clinical Hospital, Sf. Spiridon Iasi Clinical Hospital, Sf. Maria Iasi Clinical Hospital, Iasi Neurosurgery Clinical Hospital, field of activity Infectious Diseases, internal medicine, pediatrics, neurology, microbiology, parasitology, virology , intensive care

• Physiology and Pathophysiology,
• Infectious diseases,
• Medical Pathology,
• Diet therapy and special features of care in Infectious Diseases,
• General Nursing II,
• Nursing clinic

• Medical Semiology,
• Physiology, Pathophysiology,
• Infectious diseases,
• Medical Pathology,
• Microbiology,
• Diet therapy and special features of care in Infectious Diseases,
• Nursing clinic

• Lobiuc A, Dimian M, Gheorghita R, Sturdza OAC and Covasa M (2021) Introduction and Characteristics of SARS-CoV-2 in North-East of Romania During the First COVID-19 Outbreak. Front. Microbiol. 12: 654417. doi: 10.3389 / fmicb.2021.654417
• M Covasa, A Lobiuc, R Gheorghita, O Sturdza, M. Dimian- Analysis of genome characteristics and transmission of SARS-CoV-2 strains in North-East of Romania during the first COVID-19 outbreak, Microbiol. 2021, vol 12, 1879
• Olga Adriana Căliman-Sturdza. Dynamics of liver damage in SARS COV2 infection. Interdisciplinary approach to infectious pathology in a pandemic year. “Gr.T. Popa” Publishing House Iasi 2021
• Olga Adriana Caliman-Sturdza. The incidence of COVID-19 among HIV-positive patients in the epidemiological outbreak Suceava. SUPPLEMENT – Medicine in Evolution Volume XXVII, No. 1, 2021, pg.34
• Olga Adriana Caliman-Sturdza, Doina Mihalache, Catalina Mihaela Luca. “Performance of interferon-gamma release assay in the diagnosis of tuberculous meningitis in children.” Romanian Review of Laboratory Medicine, vol. 23, no. 2, pp. 199 – 212, 2015, https://content.sciendo.com/view/journals/rrlm/23/2/article-p199.xml
• Olga Adriana Caliman-Sturdza, Hepatocarcinoma – a frequent complication of viral hepatitis B and C viral etiology, BMC Infectious Diseases, vol 16 (Suppl 4): 46-7. ISSN: 1471-2334. 2016, (Proc. Of the 12th Edition of the Scientific Days of the National Institute of Infectious Diseases “Prof. Dr. Matei Balş” and the 12th National Infectious Diseases Conference)https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-016-1877-4
• Olga Adriana Caliman-Sturdza, Doina Mihalache, Catalina Mihaela Luca, Carmen Dorobat. Clinical-evolutionary aspects of tuberculous meningitis in children. Medical-Surgical Journal-Revista Medico-Chirurgicala a Societatea de Medici si Naturalisti din Iasi, 2010, vol.114, nr.3: 743-747; ISSN 00487848,
• Olga Adriana Caliman-Sturdza, Doina Mihalache, Catalina Mihaela Luca, Cristina Petrovici, Carmen Mihaela Dorobat. The usefulness of the QuantiFERON TB. Gold test in the diagnosis of tuberculous meningitis in children. Medical-Surgical Journal-Revista Medico-Chirurgicala Chirurgicala a Societatea de Medici si Naturalisti din Iasi, 2010, vol.114, nr.4: 1048-1052 ISSN 00487848,
• Olga Adriana Caliman-Sturdza, Corina Stanescu. The value of interferon-gamma blood tests for the diagnosis of tuberculosis in HIV patients. BMC Infectious Diseases, vol. 13 (Suppl 1): P1, 13-14, 2013, Proc. Of the 9th Edition of the Scientific Days of the National Institute of Infectious Diseases “Prof. Dr. Matei Balş” and the 12th National Infectious Diseases Conference)

https://bmcinfectdis.biomedcentral.com/articles/supplements/volume-13-supplement-

• Olga Adriana Caliman-Sturdza. Lyme disease – diagnosis and treatment difficulties Bucovina Medicala Magazine 2017.
• Olga Adriana Caliman-Sturdza. The role of Mediterranean diet in controlling dyslipidemia associated with HIV / AIDS. Abstract Volume of the 13th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Balș ”, November 2017: 34-35 (ISSN 2457-8525; ISSN-L 2457-8525
• Olga Adriana Caliman-Sturdza. Neurological emergencies in patients with HIV / AIDS. Bucovina Medical Magazine 2019.
• Neurological manifestation and neuroimaging aspects in patients wirth HIV / AIDS infection. Abstract Volume of the 13th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Balș ”, November 2019 ISSN
• The value of cellular interferon-gamma assays for TB diagnosis in immunocompetent and immunocompromised patients. ERJ 2007
• The role of QuantiFERON TB.Gold test in diagnosis of tuberculous meningitis. ERJ 2008
• The sensitivity and specificity of QuantiFERON TB. Gold in immunocompromised and immunocompetent patients. ERJ 2008
• The value of interferon-gamma assay for the diagnosis of TB meningitis in children. ERJ 2009
• The QuantiFERON-TB gold test at HIV patients. ERJ 2010

• Clinical study CP40617 – A phase III, multicenter, randomized, double-blind, active-controlled study to assess the efficacy and safety of baloxavirmarboxil, in combination with a neuraminidase inhibitor versus a neuraminidase inhibitor alone in hospitalized patients with severe influenza, 2018 – Presented by G. Hoffmann – La Roche Ltd, Switzerland and PPd Global Ltd, UK, Principal Investigator in the unit: Caliman Sturdza Olga Adriana
• Clinical Study 201023: “A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of hospitalized adults with influenza.” 2017-2018, funded by GlaxoSmithKilne (GSK) SRL, Romania, Principal Investigator in the unit: Caliman Sturdza Olga Adriana
• SAPPHIRE Clinical Trial, Clinical Protocol 63623872FLZ3001, multicenter, phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of pimovidir in combination with standard treatment in adolescent, adult and elderly hospitalized patients with influenza virus infections A, and DIAMOND Clinical Study, Clinical Protocol 63623872FLZ3001, multicenter, phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of pimovidir in combination with standard treatment in outpatients with influenza A virus infections are at risk of developing complications, 2018-2019, funded by Janssen Research & Development, Belgium, Principal Investigator in the unit: Caliman Sturdza Olga Adriana
• Investigator in Acti – INSP study “A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patients with acute serious influenza” 2013-2015 , funded by Activero GmbH. Investigators in the unit: Stanescu Corina and CalimanSturdza Olga Adriana
• Investigator in Seqirus V130-14 – V130_14 Protocol A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ Cell Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine or Placebo when Administrated in Healthy Subjects aged 6 Months through 47 Months A Phase III Efficacy Study with QIVc in Pediatric Subjects from 08.2019 – at present. Investigators in the Caliman-Sturdza unit Olga Adriana and Terteliu Monica.
• Principal Investigator in the international multicenter study “Diagnosis of latent infection with Mycobacterium tuberculosis by T-cell interferon-ɤ release assays in immunocompromised hosts” 2009-2010, conducted by TBNET
• Investigator in the study “Multinational comparison analysis using quantitative radiological evaluation in MAC pulmonary disease (MAPCD)” conducted by TBNET – NTM-NET, 2015-2016
• Subinvestigator in the LIPO study – lipodystrophy in patients with HIV / AIDS – 2007
• Incidence of hepatocellular carcinoma in patients diagnosed with chronic hepatitis or hepatic cirrhosis of viral etiology C, treated with Direct Antiviral Agents (DAA), in Suceava County (2019 – present)
• Monitoring of HIV-positive patients diagnosed with dyslipidemia associated with antiretroviral therapy – ongoing study – (2019 – present)
• Principal Investigator in the study: CT-P59 3.2 “A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute Respiratory Coronavirus Syndrome (SARS-CoV-2) Infection ”2020 – currently
• Principal Investigator in Study Protocol Number: SHAPERON001 Sponsor: Shaperon Inc. Protocol Title: A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in Covid-19 pneumonia patients, 2020 – present